Literature DB >> 17416416

The incidence and survival of Waldenström's Macroglobulinaemia in South East England.

K J Phekoo1, R H Jack, E Davies, H Møller, S A Schey.   

Abstract

Waldenström's Macroglobulinaemia (WM) is an uncommon B-cell lymphoproliferative disorder defined as a predominately inter-trabecular bone marrow infiltration of small lymphocytes with an IgM monoclonal gammopathy. There are little reliable incidence and survival data for the disease in the UK since epidemiological studies have usually grouped it with other plasma cell dyscrasias. This study uses data from the South Thames Haematology Register and the Thames Cancer Registry for South East England to describe the incidence and survival of WM, and the influence of selected clinical factors on survival. Between 1999 and 2001, there were 152 new cases of WM recorded in the South Thames Haematology Register, giving an age standardised rate of 0.55 per 100,000 European standard population (0.73 for males and 0.42 for females). The incidence increased with age, and the median age at diagnosis was 75 years (range 45-93 years). The estimated 5 year survival was 57% (95% CI: 47-66%). Age over 70, haemoglobin less than 10 g/L and the Eastern Cooperative Oncology Group (ECOG) Performance Status grade 3-4 at diagnosis were associated with worse survival. Between 1985 and 2002, the Thames Cancer Registry recorded 750 cases of WM occurring in the wider area of South East England. The relative 5 year survival for patients aged less than 70 years was 70% (95% CI: 60-81%) and for patients aged 70 and over it was 50% (95% CI: 41-60%).

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17416416     DOI: 10.1016/j.leukres.2007.02.002

Source DB:  PubMed          Journal:  Leuk Res        ISSN: 0145-2126            Impact factor:   3.156


  5 in total

1.  Fifty-Year Incidence of Waldenström Macroglobulinemia in Olmsted County, Minnesota, From 1961 Through 2010: A Population-Based Study With Complete Case Capture and Hematopathologic Review.

Authors:  Robert A Kyle; Dirk R Larson; Ellen D McPhail; Terry M Therneau; Angela Dispenzieri; Shaji Kumar; Prashant Kapoor; James R Cerhan; S Vincent Rajkumar
Journal:  Mayo Clin Proc       Date:  2018-04-12       Impact factor: 7.616

2.  Evolution of Management and Outcomes in Waldenström Macroglobulinemia: A Population-Based Analysis.

Authors:  Adam J Olszewski; Steven P Treon; Jorge J Castillo
Journal:  Oncologist       Date:  2016-07-29

3.  Incidence, prevalence, mortality, and causes of death in Waldenström macroglobulinemia: a nationwide, population-based cohort study.

Authors:  Seri Jeong; Seom Gim Kong; Da Jung Kim; Sangjin Lee; Ho Sup Lee
Journal:  BMC Cancer       Date:  2020-07-03       Impact factor: 4.430

Review 4.  How to manage Waldenstrom's macroglobulinemia.

Authors:  C Buske; V Leblond
Journal:  Leukemia       Date:  2013-02-06       Impact factor: 11.528

5.  Trends in Incidence and Mortality of Waldenström Macroglobulinemia: A Population-Based Study.

Authors:  Xuejiao Yin; Lei Chen; Fengjuan Fan; Han Yan; Yuyang Zhang; Zhenli Huang; Chunyan Sun; Yu Hu
Journal:  Front Oncol       Date:  2020-09-10       Impact factor: 6.244

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.